小干扰RNA
癌症研究
体内
抗体
同型
癌症
体外
化学
RNA干扰
表皮生长因子受体
核糖核酸
医学
生物
免疫学
单克隆抗体
生物化学
内科学
生物技术
基因
作者
Liyona Kampel,Meir Goldsmith,Srinivas Ramishetti,Nuphar Veiga,Daniel Rosenblum,Anna Gutkin,Sushmita Chatterjee,Moran Penn,Galya Lerman,Dan Peer,Nidal Muhanna
标识
DOI:10.1016/j.jconrel.2021.07.034
摘要
Currently there are no specific therapies addressing the distinctive biology of human papillomavirus (HPV)-induced cancer approved for clinical use. Short interfering RNA (siRNA) has much potential for therapeutic manipulation of HPV E6/E7 oncoproteins. Lipid-based nanoparticles (LNPs) can be utilized for systemic transportation and delivery of siRNA at target site. We recently developed a recombinant protein linker that enables uniform conjugation of targeting antibodies to the LNPs. Herein, we demonstrate the therapeutic efficacy of anti-E6/E7 siRNA delivered via targeted LNPs (tLNPs) in a xenograft HPV-positive tumor model. We show that anti-epidermal growth factor receptor (EGFR) antibodies, anchored to the LNPs as targeting moieties, facilitate cargo delivery but also mediate anti-tumor activity. Treatment with siE6 via tLNPs resulted in 50% greater reduction of tumor volume compared to treatment with siControl encapsulated in isoLNPs (coated with isotype control antibodies). We demonstrate superior suppression of HPV oncogenes and higher induction of apoptosis by the tLNPs both in vitro and in vivo. Altogether, the coupling of inhibitory siE6 with anti-EGFR antibodies, that further elicited anti-tumor effects, successfully restricted tumor progression. This system that combines potent siRNA and therapeutically functional tLNPs can be modulated against various cancer models.
科研通智能强力驱动
Strongly Powered by AbleSci AI